Fulcrum Therapeutics, Inc. (FULC)

NASDAQ • Healthcare

$3.68

+$0 (+0.0%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$3.68

Previous Close$3.68

Day Range$3.64 - $3.69

Avg. Volume (3M)1.4M

Market Cap$280.7M

52 Week Range

$2.83$15.74

Next EarningsIn 4 daysOct 29, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$84.9M

EPS (TTM)

-$1.21

ROA (TTM)

-26.24%

Current Ratio

31.35

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+3.4%Q3 2025-$0.28

-6.9%Q4 2025-$0.31

0.0%Q1 2026-$0.31

+19.4%Q2 2026-$0.25

-39.7%Q3 2026-$0.34

Oct 29

in 4 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -39.7%

Fulcrum Therapeutics beat consensus on adjusted EPS in the second fiscal quarter of 2026, based on preliminary results reported on July 30, 2026, with adjusted EPS of -$0.21 versus the -$0.24 estimate, about +13.7%, up from -$0.28 a year ago. Net income was a loss of about $26.2 million, down 51.4% from a loss of $17.3 million a year earlier, while gross profit came in at negative $216,000 and operating income at roughly negative $19.9 million. Operating cash flow was negative $16.0 million. Consensus for the next period calls for EPS of -$0.13.

Next report — what to expect

Fulcrum Therapeutics, Inc. (FULC) reports on October 29, 2026. Wall Street’s next-period consensus calls for EPS of -$0.11. Traders may focus on any revenue updates alongside earnings, and on whether Fulcrum extends its pattern after beating EPS in 4 of its 8 most recent quarters.

View full earnings history

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a NASDAQ-listed healthcare biotechnology company that develops medicines for genetically defined and other rare diseases in the United States. In qualitative terms, it is a clinical-stage biotech business centered on targeted drug programs, with its current portfolio led by losmapimod and FTX-6058.

Name

Fulcrum Therapeutics, Inc.

CEO

Alexander C. Sapir

Website

www.fulcrumtx.com

Industry

Healthcare

Year Founded

2015

Employees

Today's Snapshot

AI-generated

The day ended with FULC flat at 3.68, while its sector was weaker. Analysts forecast a 14-cent-per-share loss for Fulcrum Therapeutics. FULC reports earnings on 29 October.

Trading Volume

Below 10d avg (1.4M)

vs S&P 500 Today

Outperforming Market

+0.52%

Updated: October 23, 2026 at 20:18 UTC

Technical Indicators

0 Buy3 Neutral5 Sell

FULC exhibits broad weakness with the price below most short- and medium-term averages and materially under the 200-day level, and the classic pivot is effectively at current levels. Momentum indicators skew negative, driven by a significantly negative CCI while RSI and MACD are neutral-to-muted, and the trend lacks conviction with a low ADX. Volume is a concern given a large negative OBV, and volatility is subdued. Technical takeaway: Price positioned under multiple moving averages with negative volume and momentum supports a selling bias consistent with the sell rating.

All signals

EMA (5 indicators)$3.69 - $6.13
Sell
RSI (14)43.55
Neutral
Stochastic %K (14, 3, 3)31.11
Neutral
MACD Level (12, 26)-0.02
Neutral

Peers & Related Assets

OMEROmeros Corporation

$16.57-1.7%

NGNENeurogene Inc.

$23.55-3.0%

ADCTADC Therapeutics S.A.

$1.44-10.0%

CMPXCompass Therapeutics, Inc.

$0.76-5.0%

RAPTRAPT Therapeutics, Inc.

LXRXLexicon Pharmaceuticals, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.